ScienceTherapeutic Focus Areas

Graft Versus Host Disease

Fighting Against GVHD

The allogeneic transplantation of hematopoietic cells (HCT) is a well-established treatment for hematologic diseases that cannot be cured with conventional treatments.The most common life-threatening complication is Graft Versus Host Disease (GVHD), which occurs when the donated bone marrow or stem cells view the recipient’s body as foreign, and attack the recipient. The two types of GVHD are acute and chronic.

Acute graft-versus-host disease (aGVHD) is a frequent and at times unpredictably severe inflammatory complication of (HCT). Despite over decades of extensive laboratory and clinical investigation into methods to prevent severe aGVHD, this complication remains a significant cause of morbidity and mortality in allogeneic HCT recipients. Resolution of inflammation and facilitation of rapid immune reconstitution in those with only a limited response to corticosteroids is a research arena that remains an urgent clinical need.

Kamada is collaborating with Mt. Sinai to evaluate the safety and preliminary efficacy of IV AAT as preemptive therapy in patients at high risk for the development of steroid refractory GvHD after Bone Marrow Transplant (BMT).